Lantheus (NASDAQ:LNTH) Coverage Initiated by Analysts at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Lantheus (NASDAQ:LNTH) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $143.00 target price on the medical equipment provider’s stock.

A number of other analysts have also issued reports on LNTH. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities dropped their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Performance

Lantheus stock traded up $0.03 during trading hours on Wednesday, hitting $91.18. The company had a trading volume of 181,453 shares, compared to its average volume of 1,009,538. The firm has a market cap of $6.34 billion, a P/E ratio of 15.17 and a beta of 0.45. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a 50-day moving average price of $96.95 and a two-hundred day moving average price of $98.23.

Hedge Funds Weigh In On Lantheus

Large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its position in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after buying an additional 796,000 shares during the last quarter. Groupama Asset Managment acquired a new stake in Lantheus in the third quarter valued at approximately $439,000. Point72 Asset Management L.P. purchased a new position in Lantheus in the second quarter worth $26,794,000. Janus Henderson Group PLC grew its holdings in Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Lantheus during the third quarter worth $25,955,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.